Chapter 14: Opioids

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a warning system, we want it to be, like, loud.

Right.

Yeah.

Absolutely.

You want to notice it.

Right.

Think about the check engine light on your car dashboard.

You wouldn't just, you wouldn't just smash the light bulb with a hammer to make the glowing red light go away.

You'd want to pop the hood and actually fix the engine.

Exactly.

Because that light is giving you critical information.

I mean, it's a symptom, not the root disease.

It evolved to protect us from further damage.

Right.

But when you step into the world of severe pain management, sometimes the alarm itself is just so overwhelming, like so agonizing that temporarily cutting the wire to that is really the only humane option we have.

It's true.

It's a completely different paradigm.

And that brings us to the complex, heavily debated world of opioid pharmacology.

So welcome to this special last minute lecture study session.

If you are prepping for your upcoming exam, you are in the exact right place.

You really are.

Today, our mission for this deep dive into Chapter 14 is to conquer the pharmacology of opioids, exactly as it appears in your text.

We are going to translate those dense drug facts into a clear, logical story that flows from foundational physiology straight through to clinical application.

I mean, it's a vital story to understand,

especially because managing pain is truly one of clinical medicine's greatest challenges.

To start, we have to recognize that pain isn't just a single monolith.

Right.

It's not just one thing.

Exactly.

It's defined as an unpleasant sensation resulting from really complex neurochemical processes.

And it comes in two main flavors,

basically.

Nociceptive and neuropathic.

Which means we can't just throw the same drug at every single type of pain.

Not at all.

If you're dealing with mild to moderate nociceptive pain, so think of the throbbing of a sprained ankle or an arthritic joint non -opioid analgesics, like NSAIDs are your go -to.

Okay, NSAIDs for the mild stuff.

Right.

But if you're dealing with neuropathic pain, which is nerve pain, you're actually looking at anticonvulsants, tricyclic antidepressants, or like serotonin, norepinephrine reuptake inhibitors.

Wow.

Okay.

So completely different drug classes.

Yeah.

But when a patient presents with severe acute pain or chronic malignant or non -malignant pain, that's when we consider bringing in the heavy hitters, the opioids.

And what's really fascinating here is that whether these opioids are extracted directly from the poppy plant or they're semi -synthetic or even created entirely in a lab, they all share one core mechanism.

Like they aren't doing something alien to the body.

No, they're essentially biological mimics.

They act by binding to specific opioid receptors in the central nervous system.

Right.

And they just imitate the action of our body's own endogenous peptide neurotransmitters, things like endorphins, enkephalins, and dinorphins.

We are basically giving a massive exogenous dose of a pain relief chemical that the body already knows how to use.

Okay, let's untack this.

To really understand how these drugs affect the whole body, we first have to zoom way in, down to the microscopic level of the central nervous system.

I want to look at the cellular breaks.

So the major effects of opioids are mediated by three main G protein -coupled receptor families.

We designate them as Mu, Kappa, and Delta.

Mu, Kappa, and Delta.

Got it.

Right.

The Mu receptor is the primary driver of analgesic properties.

It modulates our response to thermal, mechanical, and chemical nociception.

Okay.

Then you have the Kappa receptors, which are sitting right in the dorsal horn of the spinal cord, and they also contribute to analgesia.

And finally, the Delta receptors interact more selectively with our endogenous enkephalins out in the periphery.

But regardless of which specific receptor we are targeting, they all do the same fundamental thing to the cell, right?

Chapter 14 has this incredible diagram, figure 14 .4, that shows the mechanism of action in the spinal cord.

It looks like a two -pronged attack at the synapse.

It is a two -pronged attack.

Picture the synapse between two neurons.

You have the presynaptic neuron trying to send the pain signal and the postsynaptic neuron trying to receive it.

Okay, I'm picturing it.

When an opioid binds to the receptor on that presynaptic neuron, it physically decreases the influx of calcium ions into the cell.

And calcium is the trigger that tells the cell to dump its neurotransmitters.

Exactly.

So less calcium means less of the excitatory neurotransmitters, like glutamate spilling into the synaptic cleft.

It's like cutting off the power supply to a PA system.

The presynaptic neuron simply can't broadcast the message.

That's a great way to put it.

But the body builds in redundancies, so opioids attack the receiving end as well.

On the postsynaptic neuron, activating the opioid receptor opens up potassium channels.

Oh, and potassium is positively charged.

Right, and it rushes out of the cell.

Losing positive charge makes the inside of the cell more negative.

That's hyperpolarization.

Spot on.

So even if a little bit of that glutamate signal squeaks through from the first neuron, this second neuron requires a massive stimulus to fire an action potential.

So it's like heavily soundproofing the room.

The receiving neuron is basically deaf to the signal.

That is the perfect way to look at it.

Cutting the power and soundproofing the room.

And now that we know how those cellular brakes work, we can look at what happens when you slam on them using the pro -typical strong mu receptor agonist morphine.

Ah, morphine.

The gold standard.

It really is the standard we compare all other opioids to.

And it interacts stereospecifically with opioid receptors, not just in the CNS, but in other anacomic structures too, like the GI tract and the urinary bladder.

Let's follow that physiology, starting with the most obvious therapeutic effect, analgesia and euphoria.

Morphine relieves pain by raising the pain threshold at the spinal cord level and altering the brain's perception of the pain.

But the euphoria, that like powerful sense of contentment, that isn't just an absence of pain, is it?

No, not at all.

It's an active neurochemical shift.

Morphine actually disinhibits the dopamine -containing neurons in the ventral tegmental area of the brain.

Wait, it disinhibits them?

Yeah, by taking the brakes off those neurons, it lets dopamine flow more freely, which creates that euphoric rush.

Wow.

But every action has a reaction.

Let's talk about respiration, because I know this is the big one for exams.

Oh, it is the most critical side effect.

Morphine causes respiratory depression by reducing the responsiveness of the medullary respiratory center to carbon dioxide.

Okay, so normally when CO2 builds up in your blood, your brain screams, take a breath.

Right, but morphine suppresses that panic button.

And this can happen with ordinary doses in patients who are opioid -naive.

If the dose is too high, respiration just ceases entirely.

It is the most common cause of death in an acute opioid overdose.

Wait a second.

If their breathing slows down, they retain carbon dioxide.

Doesn't high CO2 cause blood vessels in the brain to dilate?

It does.

And dilated vessels increase cerebrospinal fluid pressure.

Oh, so that explains the contraindication for head trauma.

If someone already has a severe brain injury, giving them morphine increases the pressure inside their skull, which could be catastrophic.

You nailed it.

You always have to trace the physiology.

Let's look at another classic physical sign.

Figure 14 .8 shows a close -up of a patient's eye with a characteristic pinpoint pupil, known as meiosis.

Right, pinpoint pupils.

Stimulation of mo and kappa receptors causes this.

So why is this pinpoint pupil so diagnostically important, like for a multiple -choice question or a real -life ER?

Because there is very little tolerance to this effect.

If you have an unconscious patient struggling to breathe, I mean, many things could cause a coma, but most of them cause the pupils to dilate.

If you see respiratory depression in pinpoint pupils, it is a massive red flag for opioid overdose.

That makes sense.

Another system that gets heavily impacted is the GI tract.

Morphine decreases motility and increases sphincter tone, so it causes opioid -induced constipation, or OIC.

And just like the pinpoint pupils, patients develop almost no tolerance to this constipation over time.

Which leads right into a major clinical reality.

If you are prescribing morphine, you should proactively initiate a non -prescription stimulant laxative like Sena as part of a bowel regimen.

You don't wait for the constipation to happen.

You prevent it.

Right.

Don't wait.

Let's touch on two more physiological quirks with morphine before we move on.

First, it releases histamine from mast cells, meaning it can cause urticaria, sweating, and vasodilation.

But histamine also causes bronchoconstriction.

So if you're looking at a patient with severe asthma, morphine requires extreme caution.

Second, there's a hormonal effect,

right?

Opioid -induced androgen deficiency, or OP -AID?

Yeah.

Prolonged use suppresses the hypothalamic -pituitary -gonadal axis.

This leads to decreased testosterone production, which clinically manifests as fatigue, depression, and decreased muscle mass in chronic users.

Now I really want to zoom in on how the body gets rid of morphine, because it dictates a massive clinical decision.

Morphine undergoes significant first -pass metabolism in the liver.

It's conjugated into two main metabolites, morphine -6 -glucuronide, or M6G, and morphine -3 -glucuronide, or M3G.

And those metabolites are highly active.

M6G is a very potent analgesic.

Actually, it's more potent than morphine itself.

Wow, really?

Yeah.

And M3G doesn't relieve pain, but it is neuro -excitatory.

And the key here is that both of these active metabolites are excreted by the kidneys.

Ah, okay.

So if you are staring at a pharmacology question asking you to treat a patient with renal dysfunction,

morphine is a trap.

A huge trap.

Those active metabolites are going to accumulate in the failing kidneys.

They can cause fatal respiratory depression from the M6G, or delirium and neuro -excitation from the M3G.

Oh, and before we move on, we have to establish the black box warning for all opioids.

Yes, guidelines strongly urge avoiding the simultaneous prescribing of opioids and benzodiazepines.

Both are profound CNS depressants.

Combining them exponentially amplifies the risk of fatal respiratory depression.

Okay, so if morphine is the ultimate sledgehammer, but it's dangerous for patients with bad kidneys or asthma, we obviously need alternatives.

Let's look at the phenanthrenes and semisynthetics.

Starting with codeine.

Codeine is a weak, mook opioid agonist used for mild to moderate pain.

But the trick with codeine is that it's essentially a pro -drug.

A pro -drug?

Yeah, its analgesic action depends almost entirely on the liver enzyme CYP2D6, converting it into morphine inside the body.

And because genetics dictate enzyme levels, we run into the danger of ultra -rapid metabolizers.

Exactly.

If a patient genetically has a highly active CYP2D6 enzyme, they convert that weak codeine into a massive dose of morphine very quickly, leading to toxicity.

That's terrifying.

It is.

The text specifically highlights the danger here for children.

There have been tragic reports of life -threatening respiratory depression and death in children who received codeine after having their tonsils or adenoids removed.

Which is why we prefer non -obioids like dextromethorphin for cough suppression anyway.

Okay, what about oxycodone and oxymorphone?

Oxycodone is about twice as potent as oral morphine, is metabolized mainly by two liver enzymes, CYP2D6 and CYP3A4, and is often combined with acetaminophen.

Oxymorphone is even stronger, and uniquely, it doesn't rely heavily on those CYP enzymes, meaning it has fewer clinically relevant drug interactions.

Nice.

Let's talk about hydromorphone, because this directly solves the clinical problem we just discussed with morphine's active metabolites.

Oral hydromorphone is four to seven times more potent than oral morphine.

Right.

But crucially, it's preferred over morphine for patients with renal dysfunction.

Why?

Because it metabolizes differently and causes far less accumulation of active metabolites in the kidney.

Exactly.

It's a much safer profile for renal impairment.

You also have hydrocodone, which is weaker, comparable to oral morphine, and like codeine, it relies on that CYP2D6 enzyme to get converted into hydromorphone.

Got it.

Yeah.

So far, we've been talking about natural or semi -synthetic structures.

But what happens when pharmaceutical chemistry designs an opioid from scratch?

We get the synthetics, where potency and pharmacokinetic quirks go to the extreme, and the most notorious character here is fentanyl.

Oh, fentanyl.

It's a synthetic opioid that has a hundred times the analgesic potency of morphine.

A hundred times?

Yes.

It is highly lepophilic, meaning it loves fat and dissolves easily through cell membranes.

Because of this, it crosses the blood -brain barrier instantly, giving it a very rapid onset and a very short duration of action, just 15 to 30 minutes when given intravenously.

OK, let me push back on that for a second.

If it's incredibly fast -acting with a super -short duration, why is a transdermal fentanyl patch a thing?

A patch implies long -term, slow release.

That's a great observation, and it's a critical mechanism to understand.

The patch works by using the patient's own body fat.

It creates a reservoir of the drug in the skin itself.

Oh, wow.

So while the drug crosses membranes easily, building up that skin reservoir takes time.

The patch has a delayed onset of at least 12 hours.

Which completely dictates how we use it.

You would never use a fentanyl patch for acute or post -operative pain.

By the time the pain relief kicks in 12 hours later, the acute pain crisis might be over or worse.

You overdose a patient who isn't tolerant to opioids.

It is strictly for the management of chronic severe pain in opioid -tolerant patients.

It's vital to respect that potency.

And the text mentions its even stronger synthetic cousins like so fentanyl, and particularly carfentanil, which is 100 times more potent than fentanyl.

Wow.

Carfentanil isn't used clinically in humans, but it's a major toxicological threat because it's illicitly laced into street heroin.

Okay, let's look at another synthetic that solves a different clinical problem.

Methadone.

Methadone is unique.

It's a mu receptor agonist, but it also does two other things.

It's an antagonist of the NMDA receptor, which is a receptor involved in pain transmission, and it inhibits the reuptake of norepinephrine and serotonin.

So it's a triple threat.

Exactly.

Because of this triple threat mechanism, it dampens the pain signals across multiple pathways,

making it incredibly useful for treating both nociceptive pain and that tricky neuropathic nerve pain.

Here's where it gets really interesting, though.

The pharmacokinetics of methadone are a total trap if you aren't paying attention.

Oh, the PK trap.

Methadone is very lipophilic, meaning it redistributes deeply into fat stores and releases very slowly.

Its terminal half -life, so how long it takes the body to clear it, ranges from 12 to 40 hours, and can even extend up to 150 hours.

150 hours.

But the actual duration of analgesia, like the pain relief the patient feels, only lasts 4 to 8 hours, so it's like a dense, slow -leaking sponge.

That's exactly it.

The surface of the sponge feels dry, meaning the pain relief has worn off after 6 hours.

So the patient takes another dose, the pain goes away, but the sponge itself is still deeply soaked with the drug from the first dose.

It's barely been eliminated.

So if you dose methadone purely based on when the pain returns, you are just soaking an already full sponge.

It accumulates dangerously in the tissue, leading to extreme toxicity and delayed respiratory depression.

You also have to monitor the heart, as methadone can prolong the QTC interval and cause a dangerous arrhythmia called torsades de pointes.

Another synthetic that demands respect is meparadine.

It acts primarily as a kappa agonist with some muactivity.

It's very lipophilic and has anti -cholinergic effects.

Which explains why it causes delirium.

Anti -cholinergic drugs block acetylcholine, which frequently causes confusion and delirium, especially in the elderly.

But the real timer on meparadine is its active metabolite, normaparidine.

Right, normaparidine is neurotoxic.

If it accumulates, especially in patients with renal insufficiency, it causes hyperreflexia, myoclonus, and frank seizures.

Seizures, yikes.

Because of this, meparadine should only be used for short -term pain management, 48 hours or less.

And you must never mix it with older antidepressants like MAOIs or newer ones like SSRIs, because it alters serotonin levels and risks fatal serotonin syndrome.

So we've talked about full agonists that slam down on the cellular brakes.

But what if we want the pain relief of an opioid, but we want to install a speed governor to prevent that fatal respiratory depression?

That brings us to the partial agonists and mixed agonist antagonists.

These drugs bind to the opioid receptor, but they have less intrinsic activity than full agonists.

They create a sealing effect.

You can increase the dose of the drug, but the pharmacologic effect, including the dangerous respiratory depression, eventually caps out and won't go any higher.

And the star of this class is buprenorphine.

It's a potent partial agonist at the mu receptor and an antagonist at the kappa receptors.

What's fascinating about buprenorphine is its affinity.

It binds to the mu receptor incredibly tightly, so tightly, in fact, that if you give it to a patient who is already dependent on a full agonist like heroin or methadone, it will physically rip the full agonist off the receptor and take its place.

It's like a massive bouncer at a nightclub.

It kicks the rowdy patron heroin out of the club and then just stands in the doorway.

Because it's only a partial agonist, it doesn't cause the same high, but because it's standing in the doorway, no other opioids can get in.

That bouncer effect is what precipitates immediate severe withdrawal symptoms if you give it to someone currently high on heroin.

But it is also what makes it an incredible tool for opiate detoxification.

Figure 14 .11 in the text compares the withdrawal severity of different drugs.

Heroin withdrawal is a massive severe spike of agony that ends relatively quickly.

Methadone withdrawal is a lower peak, but it drags on for weeks.

Buprenorphine hits the sweet spot.

It causes a shorter and less severe withdrawal than methadone.

Plus, unlike methadone, which requires specialized clinics, buprenorphine is approved for office -based prescription treatment of opioid dependence.

There are a couple cautions, though.

It can prolong the QDC interval, and because that bouncer binds so tightly, if a patient does overdose on buprenorphine, the standard doses of our reversal agent, naloxone, might not be strong enough to knock it off the receptor.

Briefly, there are other mixed agents, too.

Pentazocene acts as a kappa agonist and weak mu antagonist, or partial agonist.

But it can cause hallucinations and actually increases blood pressure, so you avoid it in coronary artery disease.

Then there's nalbufene and betorfenol, which exhibit that safety -sealing effect for respiratory depression.

Betorfenol even comes in a nasal spray for severe headaches.

Let's round out the analgesics with the other centrally acting agents.

These are drugs that bind to the mu receptor but heavily rely on inhibiting the reuptake of neurotransmitters like norepinephrine and serotonin to dampen the pain signal.

First, tapentadol.

Tapentadol is a mu agonist and an inhibitor of norepinephrine reuptake.

It's highly effective for neuropathic pain, like diabetic peripheral neuropathy, and crucially, it is metabolized by glucuronidation into inactive metabolites.

It doesn't use the tricky CYP450 liver enzymes.

Which means it lacks those complex drug interactions, and it's safe for mild to moderate renal impairment because there are no active metabolites to accumulate.

It's a very clean clinical profile.

But then we have tramadol.

It binds the mu receptor and weakly inhibits norepinephrine and serotonin reuptake.

It's metabolized by CYP2D6 into a much more active metabolite.

So what is the physiologic danger here?

There are two massive red flags with tramadol.

First, because much of its pain relief comes from altering serotonin and norepinephrine, If a patient overdoses, our opioid reversal agent naloxone only partially reverses the toxicity.

Oh, that's scary.

Second, tramadol lowers the seizure threshold.

It also carries a high risk of serotonin syndrome if combined with SSRIs, MAOIs, or tricyclic antidepressants because you are stacking drugs that all increase serotonin in the brain.

You must use it with extreme caution in anyone with a history of seizures.

Okay, we've explored how all these drugs work, how they accumulate in fat and kidneys, and how they interact.

Finally, we need to know how to hit the undo button when things go catastrophically wrong.

The antagonists.

Alright, naloxone.

It is a competitive antagonist with the highest affinity for the mu receptor.

It doesn't do anything if you aren't taking opioids, but if you are, it rapidly displaces all receptor -bound opioid molecules.

Given intravenously, it can reverse coma and respiratory depression within 1 -2 minutes.

But there is a massive pharmacokinetic mismatch here.

The half -life of naloxone is only 30 -81 minutes.

This is a life or death detail.

If a patient overdoses on a long -acting opioid like methadone or an extended -release oxycodone, you give them naloxone and they wake up, they breathe, but 45 minutes later the naloxone wears off and leaves the receptor.

But that long -acting opioid is still circulating in their blood, so it rebinds to the receptor and the patient lapses right back into respiratory depression.

Exactly, you have to keep monitoring them and likely re -dose the naloxone.

Chapter 14 points out how crucial community availability of naloxone is now, with nasal strays and auto -injectors.

As a prescriber, emergency counseling for the patient and family is non -negotiable, especially for patients with underlying respiratory risks like COPD or sleep apnea.

Just to contrast, we also have naltrexone.

It's an antagonist similar to naloxone but has a much longer duration of action and can be given orally.

A single dose blocks the effects of injected heroin for up to 24 hours.

It's used for rapid detox and maintenance, but it does carry a risk of hepatotoxicity, so you have to monitor liver function.

It is honestly mind -blowing to consider the scale of what we've just covered.

We are manipulating a system that evolved over millions of years.

It really is, this entire massive pharmaceutical landscape with all its varied receptor affinities, its dangerous active metabolites, its profound body -wide impacts from your breathing to your GI tract.

It all exists simply because humans figured out how to biochemically hijack the endogenous pain management system.

Our bodies were already running via natural endorphins.

We just figured out how to synthesize the key to our own internal locks.

It leaves you marveling at the sheer complexity of human physiology.

It's a powerful tool, but as we've seen, one that requires immense respect and understanding of the underlying chemistry.

So what does this all mean for you?

It means you now understand the mechanisms, the targets, and the clinical realities of Chapter 14.

You know why the dashboard warning light goes off and exactly how the chemical brakes stop the signal.

We hope this deep dive has clarified the muddy waters of opioid pharmacology for you.

From everyone here on the Last Minute Lecture Team, thank you for joining us and good luck on your exam.